Floatz logo

RAMIPRIL

Hypertension

University of MichiganSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Hypertension cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
University of Kansas Medical Center
Phase 4BBB
VALSARTAN
University of Alabama at Birmingham
Phase 4BBB
AMLODIPINE
Jing Liu
Phase 4BBB
Losartan
Rong Zhang
Phase 4BBB
Trandolapril
University of Florida
Phase 4BBB

View all 50 →

Same molecule, other indications

RAMIPRIL is also rated in:

coronary atherosclerosisDormant
BB
Indicative ·
64 / 100
View asset →
iatrogenicDormant
BB
Indicative ·
64 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →